Dementia and Alzheimer Disease

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 23, 2022.

These were the most-watched interviews with experts in dementia that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.

As part of NeurologyLive®'s Year in Review, we've compiled the most-read feature-length stories that appeared on the website in 2022.

Drs Atri and Cohen discuss biomarkers for Alzheimer’s disease and the challenges in their use in routine practice.

Four Alzheimer’s disease expert discuss our current understanding of Alzheimer’s disease pathology and the presence of amyloid and tau pathologies in patients.

As part of NeurologyLive®'s Year in Review, we've compiled the most-read question-and-answer interviews we've conducted with experts in various neurology specialties in 2022.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news stories in Alzheimer disease and dementia in 2022.

The request to reverse CMS’s April 2022 decision is based on new data on lecanemab, an antiamyloid therapy from Biogen/Eisai that is currently under FDA review until January 6, 2023.

The cognitive and behavioral neurology fellow at Pitié-Salpêtrière Hospital in Paris, France, provided background on a study presented at CTAD 2022 assessing the efficacy of prominent, up-and-coming anti-amyloid therapies. [WATCH TIME: 7 minutes]

The professor of clinical geriatric epidemiology at Karolinska Institutet provided perspective on the FINGERS trial, the first study to show it is possible to prevent cognitive decline using a multidomain lifestyle intervention.

The chief medical officer of Alzheon detailed the phase 2 safety findings of ALZ-801, and the lack of amyloid-related imaging abnormalities observed. [WATCH TIME: 3 minutes]

James Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine, provided insight on the unmet needs for dementia with Lewy bodies, and whether success in Alzheimer disease can help.

The senior VP of clinical research at Eisai discussed findings from a phase 2 study assessing irsenontrine in patients with dementia with Lewy bodies and Parkinson disease dementia. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 16, 2022.

Almost 3 years since the beginning of the pandemic, continuous research efforts have begun to paint a better picture of the impact the virus has on the brain and the central nervous system.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Marwan Sabbagh, MD, FAAN. [LISTEN TIME: 21 minutes]

The chief executive officer and co-founder of Linus Health discussed screening tools for early cognitive decline and overcoming the complexities with using new-age technology. [WATCH TIME: 3 minutes]

The chief medical officer of Alzheon detailed the efficacy, safety, and potential of ALZ-801, an investigational anti-amyloid therapy being assessed in high-risk individuals with early Alzheimer disease.

The chief medical officer of Alzheon discussed the impact a therapy like ALZ-801 can have on the overall Alzheimer community considering its effects on carriers of APOE e4 alleles. [WATCH TIME: 3 minutes]

Bjoern Schelter, MD, Data Analytics and Biostatistics lead at TauRx, provided background on the efficacy, safety, and role of HMTM as a treatment for cognition in pre-Alzheimer disease stages like mild cognitive impairment.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Howard Fillit, MD, founding executive director of the Alzheimer’s Drug Discovery Foundation, provided perspective on how ADDF and others are advancing the detection and treatment of Alzheimer disease.

The chief executive officer and co-founder of Linus Health provided perspective on the state of clinical trials for Alzheimer disease, and how technology can play a major role in advancing therapeutics going forward. [WATCH TIME: 4 minutes]